Large Molecule Patents
Xolair is a drug owned by Genentech, Inc.. It is protect by 3 US patents. Given below is the list of those patents along with their expiration dates.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US12030959 | GENENTECH, INC. | Anti-IgE antibody therapy for multiple food allergies |
Jul, 2043
(18 years from now) | Active |
| US11987637 | GENENTECH, INC. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
Jul, 2028
(3 years from now) | Active |
| US10034940 | GENENTECH, INC. | High concentration antibody and protein formulations |
Nov, 2025
(11 months from now) | Active |
Xolair's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
About Xolair
Active Ingredients:
Xolair contains Omalizumab as an active ingredient
Approval Date:
Xolair was first approved for market use on 20 Jun, 2003.
Dosage:
Xolair is available in 4 strengths and the following dosage forms are - For Injection form for Subcutaneous use, Injection form for Subcutaneous use, Injection form for Subcutaneous use.
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 150MG | For Injection | Rx | Subcutaneous |
| 150MG | For Injection | Rx | Subcutaneous |
| 150MG/ML | Injection | Rx | Subcutaneous |
| 150MG/ML | Injection | Rx | Subcutaneous |
| 150MG/ML | Injection | Rx | Subcutaneous |
| 150MG/ML | Injection | Rx | Subcutaneous |
| 300MG/2ML | Injection | Rx | Subcutaneous |
| 300MG/2ML | Injection | Rx | Subcutaneous |
| 75MG/0.5ML | Injection | Rx | Subcutaneous |
| 75MG/0.5ML | Injection | Rx | Subcutaneous |
| 75MG/0.5ML | Injection | Rx | Subcutaneous |
| 75MG/0.5ML | Injection | Rx | Subcutaneous |